Marinol dronabinol data

UMED announced that results of a preliminary study showed reduced symptoms of anorexia and disturbed behavior in Alzheimer's patients. In a presentation at the International Conference on Alzheimer's Disease and Related Disorders in Osaka, Japan, Marinol was shown to help these symptoms in the 12 patients tested. Half of the patients received the product for the first six weeks and then placebo for another six weeks; the others received placebo first and then Marinol. The patients were hospitalized with probable Alzheimer's and refusing food.

Three patients dropped out of the study due to either a seizure after the first dose (one patient) or infections. Side effects associated with the drug included euphoria, somnolence, and tiredness. ...